TUSTIN, Calif., April 25 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), an international biopharma company with development and manufacture of proprietary pharmaceutical and diagnostic products in China, announced today that a 4th Quarter Update and Year End Report on AMDL has been posted by analyst Lauren Rudd at (http://www.RuddReport.com). It includes a 12 month target price of $23 and a Buy Recommendation.
The Report highlights AMDL's recent and anticipated company goals and objectives in regards to DR-70(TM), Human Papilloma Virus (HPV), Jade Pharmaceutical Inc. 2008 business expansion and JPGreen Health & Beauty Clinics. It also covers various Peer Group Comparison & Valuation Analysis and their views and opinions on financial performance for FY2008.
The 21-page report goes into significant detail about AMDL's products, particularly AMDL's recent announcement in April 2008 that it has entered into an exclusive sublicense agreement for a diagnostic product for in-vitro genotype testing in women with Human Papilloma Virus (HPV), a potential billion dollar market.
"AMDL has had another profitable quarter, making it two in a row, a trend we feel goes a long way towards reaffirming our current projections that by the end of 2008, revenues from Jade alone will reach or exceed $38 million," Mr. Rudd writes.
About Jade Pharmaceutical Inc.: Jade has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiary, Jade currently manufactures large volume injectable fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.
About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com.
Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.
Disclaimer by Rudd
This disclaimer is an integral part of Rudd's service. Please read it before investing in any security on which we report.
Opinions are solely those of the staff of The Rudd Report and are subject to change without notice. Our reports are for information only and we do not offer securities or solicit the offer of securities of any company. Our reports are to inform the public and not to promote any company or its securities.
We do not inform any company in advance of the nature or conclusions of our reports nor can a company change what we write.
In the case of AMDL we received a fee for coverage of the current quarter in the amount of $6,000.
Our reports contain factual statements and opinions. We derive these
factual statements from sources that we believe are accurate. However, we
do not represent that the facts presented are accurate or complete.
Furthermore, the information contained in this report may become inaccurate
because of the passage of time and should therefore be read for historical
Contact: AMDL, Inc.
Mr. Paul Knopick
AMDL Investor Relations
Direct Line: 949.707.5365
Voice Mail: 714.505.4460
|SOURCE AMDL, Inc.|
Copyright©2008 PR Newswire.
All rights reserved